vs
AIM ImmunoTech Inc.（AIM）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是AIM ImmunoTech Inc.的38357.1倍（$805.5M vs $21.0K）。NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -19881.0%，领先19900.0%）。NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs -53.3%）。过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs -27.5%）
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
AIM vs NBIX — 直观对比
营收规模更大
NBIX
是对方的38357.1倍
$21.0K
营收增速更快
NBIX
高出81.7%
-53.3%
净利率更高
NBIX
高出19900.0%
-19881.0%
两年增速更快
NBIX
近两年复合增速
-27.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0K | $805.5M |
| 净利润 | $-4.2M | $153.7M |
| 毛利率 | — | 97.8% |
| 营业利润率 | -14057.1% | 26.2% |
| 净利率 | -19881.0% | 19.1% |
| 营收同比 | -53.3% | 28.3% |
| 净利润同比 | 30.0% | 49.1% |
| 每股收益（稀释后） | $-6.46 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIMNBIX
| Q4 25 | $21.0K | $805.5M | ||
| Q3 25 | $26.0K | $794.9M | ||
| Q2 25 | $25.0K | $687.5M | ||
| Q1 25 | $16.0K | $572.6M | ||
| Q4 24 | $45.0K | $627.7M | ||
| Q3 24 | $35.0K | $622.1M | ||
| Q2 24 | $50.0K | $590.2M | ||
| Q1 24 | $40.0K | $515.3M |
净利润AIMNBIX
| Q4 25 | $-4.2M | $153.7M | ||
| Q3 25 | $-3.3M | $209.5M | ||
| Q2 25 | $-2.8M | $107.5M | ||
| Q1 25 | $-3.7M | $7.9M | ||
| Q4 24 | $-6.0M | $103.1M | ||
| Q3 24 | $-3.7M | $129.8M | ||
| Q2 24 | $-1.8M | $65.0M | ||
| Q1 24 | $-5.8M | $43.4M |
毛利率AIMNBIX
| Q4 25 | — | 97.8% | ||
| Q3 25 | — | 98.2% | ||
| Q2 25 | — | 98.4% | ||
| Q1 25 | — | 98.4% | ||
| Q4 24 | — | 98.5% | ||
| Q3 24 | — | 98.7% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 98.5% |
营业利润率AIMNBIX
| Q4 25 | -14057.1% | 26.2% | ||
| Q3 25 | -9411.5% | 30.1% | ||
| Q2 25 | -10584.0% | 21.2% | ||
| Q1 25 | -22618.8% | 4.1% | ||
| Q4 24 | -13011.1% | 22.6% | ||
| Q3 24 | -12825.7% | 29.5% | ||
| Q2 24 | -7388.0% | 24.6% | ||
| Q1 24 | -14335.0% | 19.3% |
净利率AIMNBIX
| Q4 25 | -19881.0% | 19.1% | ||
| Q3 25 | -12630.8% | 26.4% | ||
| Q2 25 | -11176.0% | 15.6% | ||
| Q1 25 | -23156.3% | 1.4% | ||
| Q4 24 | -13260.0% | 16.4% | ||
| Q3 24 | -10571.4% | 20.9% | ||
| Q2 24 | -3672.0% | 11.0% | ||
| Q1 24 | -14542.5% | 8.4% |
每股收益（稀释后）AIMNBIX
| Q4 25 | $-6.46 | $1.49 | ||
| Q3 25 | $1.57 | $2.04 | ||
| Q2 25 | $-3.68 | $1.06 | ||
| Q1 25 | $-0.05 | $0.08 | ||
| Q4 24 | $-21.80 | $1.00 | ||
| Q3 24 | $-6.00 | $1.24 | ||
| Q2 24 | $-3.00 | $0.63 | ||
| Q1 24 | $-0.12 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $713.0M |
| 总债务越低越好 | $4.5M | — |
| 股东权益账面价值 | $-9.8M | $3.3B |
| 总资产 | $5.8M | $4.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AIMNBIX
| Q4 25 | $3.0M | $713.0M | ||
| Q3 25 | $2.4M | $340.2M | ||
| Q2 25 | $835.0K | $264.0M | ||
| Q1 25 | $2.2M | $194.1M | ||
| Q4 24 | $4.0M | $233.0M | ||
| Q3 24 | $7.2M | $349.1M | ||
| Q2 24 | $10.1M | $139.7M | ||
| Q1 24 | $10.9M | $396.3M |
总债务AIMNBIX
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $3.3M | — |
股东权益AIMNBIX
| Q4 25 | $-9.8M | $3.3B | ||
| Q3 25 | $-6.1M | $3.0B | ||
| Q2 25 | $-6.5M | $2.7B | ||
| Q1 25 | $-3.9M | $2.5B | ||
| Q4 24 | $-1.3M | $2.6B | ||
| Q3 24 | $2.9M | $2.7B | ||
| Q2 24 | $6.1M | $2.5B | ||
| Q1 24 | $4.8M | $2.4B |
总资产AIMNBIX
| Q4 25 | $5.8M | $4.6B | ||
| Q3 25 | $5.5M | $4.3B | ||
| Q2 25 | $4.1M | $3.9B | ||
| Q1 25 | $6.2M | $3.7B | ||
| Q4 24 | $8.6M | $3.7B | ||
| Q3 24 | $13.6M | $3.5B | ||
| Q2 24 | $15.7M | $3.3B | ||
| Q1 24 | $16.2M | $3.5B |
负债/权益比AIMNBIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | — | $386.0M |
| 自由现金流率自由现金流/营收 | — | 47.9% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | — | $743.9M |
8季度趋势，按日历期对齐
经营现金流AIMNBIX
| Q4 25 | $-2.0M | $388.4M | ||
| Q3 25 | $-5.1M | $227.5M | ||
| Q2 25 | $-1.5M | $102.0M | ||
| Q1 25 | $-2.4M | $64.8M | ||
| Q4 24 | $-4.0M | $242.5M | ||
| Q3 24 | $-3.1M | $158.0M | ||
| Q2 24 | $-3.0M | $64.6M | ||
| Q1 24 | $-4.8M | $130.3M |
自由现金流AIMNBIX
| Q4 25 | — | $386.0M | ||
| Q3 25 | — | $214.3M | ||
| Q2 25 | — | $89.5M | ||
| Q1 25 | — | $54.1M | ||
| Q4 24 | — | $235.2M | ||
| Q3 24 | — | $149.9M | ||
| Q2 24 | — | $53.0M | ||
| Q1 24 | — | $119.1M |
自由现金流率AIMNBIX
| Q4 25 | — | 47.9% | ||
| Q3 25 | — | 27.0% | ||
| Q2 25 | — | 13.0% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 37.5% | ||
| Q3 24 | — | 24.1% | ||
| Q2 24 | — | 9.0% | ||
| Q1 24 | — | 23.1% |
资本支出强度AIMNBIX
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 2.2% |
现金转化率AIMNBIX
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 8.20× | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AIM
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
